The sale of a long-established manufacturing site to a US pharmaceutical specialist highlights the potential for facility repurposing to support Ireland’s expanding pharmaceutical manufacturing base.

Nestlé has agreed to sell its former infant formula manufacturing facility in Askeaton, Co Limerick, to US pharmaceutical group Pfanstiehl, creating the potential for continued manufacturing activity at the site. The facility, formerly operated as Wyeth Nutritionals, closed in March 2026 following a two-year wind-down that resulted in the loss of 542 jobs. Nestlé said the sale represents a successful outcome in its efforts to identify a new owner capable of sustaining the site's manufacturing heritage.

For Ireland's pharmaceutical industry, the transaction is significant because Pfanstiehl specialises in the development and manufacture of high-purity injectable excipients and components used across biopharmaceutical applications. The company supplies materials for areas including protein and antibody drugs, vaccines, and cell and gene therapies, according to Pfanstiehl. This makes the acquisition potentially relevant to several of the industry's higher-value manufacturing segments.

The acquisition would also establish a new manufacturing presence in Ireland for Pfanstiehl. The company established Pfanstiehl Ireland Limited in January 2026 but has historically operated its manufacturing facilities in the United States. The Irish Times reported that the Askeaton facility is therefore likely to become the company's first manufacturing base outside the US.

However, the transition from infant formula production to pharmaceutical manufacturing will require substantial technical and regulatory work. The facility would need to be adapted to meet pharmaceutical manufacturing requirements and ultimately obtain the relevant regulatory clearances. The timeline, investment level, employment plans and operational start date have not yet been disclosed, meaning the future scale of the operation remains uncertain.

The site's existing manufacturing heritage could nevertheless provide a valuable foundation for future development. The Askeaton facility dates back to the 1970s and has previously supported large-scale production and research and development activities.

For the sector, the lesson is clear: repurposing established manufacturing infrastructure can provide another route for expanding Ireland's pharmaceutical capacity, provided facilities can be successfully adapted to meet the demanding requirements of regulated production. The Askeaton transaction could therefore become an important example of how existing industrial assets can be transitioned towards higher-value pharmaceutical and biopharmaceutical manufacturing.

Source: The Irish Times / Arup / Nestlé